MX393313B - Metodos de tratamiento de tumores neuroepiteliales usando moduladores selectivos del receptor de glucocorticoide. - Google Patents
Metodos de tratamiento de tumores neuroepiteliales usando moduladores selectivos del receptor de glucocorticoide.Info
- Publication number
- MX393313B MX393313B MX2019015385A MX2019015385A MX393313B MX 393313 B MX393313 B MX 393313B MX 2019015385 A MX2019015385 A MX 2019015385A MX 2019015385 A MX2019015385 A MX 2019015385A MX 393313 B MX393313 B MX 393313B
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- sgrm
- tumor
- glucocorticoid receptor
- neuroepithelial
- Prior art date
Links
- 208000027831 neuroepithelial neoplasm Diseases 0.000 title abstract 5
- 229940117965 Glucocorticoid receptor modulator Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 abstract 2
- 101800000414 Corticotropin Proteins 0.000 abstract 2
- 102100027467 Pro-opiomelanocortin Human genes 0.000 abstract 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 abstract 2
- 229960000258 corticotropin Drugs 0.000 abstract 2
- 230000003637 steroidlike Effects 0.000 abstract 2
- YJDDXMSIMBMMGY-UHFFFAOYSA-N 2-cyclohexylpyrimidine Chemical compound C1CCCCC1C1=NC=CC=N1 YJDDXMSIMBMMGY-UHFFFAOYSA-N 0.000 abstract 1
- 206010014967 Ependymoma Diseases 0.000 abstract 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 abstract 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 abstract 1
- 102000007517 Neurofibromin 2 Human genes 0.000 abstract 1
- 108010085839 Neurofibromin 2 Proteins 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- -1 heteroaryl ketone Chemical class 0.000 abstract 1
- 206010027191 meningioma Diseases 0.000 abstract 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical group C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 abstract 1
- 229960003248 mifepristone Drugs 0.000 abstract 1
- 208000007538 neurilemmoma Diseases 0.000 abstract 1
- 208000002761 neurofibromatosis 2 Diseases 0.000 abstract 1
- 208000022032 neurofibromatosis type 2 Diseases 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 206010039667 schwannoma Diseases 0.000 abstract 1
- 230000003248 secreting effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762522489P | 2017-06-20 | 2017-06-20 | |
| PCT/US2018/038075 WO2018236749A2 (en) | 2017-06-20 | 2018-06-18 | Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX393313B true MX393313B (es) | 2025-03-24 |
Family
ID=64737393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019015385A MX393313B (es) | 2017-06-20 | 2018-06-18 | Metodos de tratamiento de tumores neuroepiteliales usando moduladores selectivos del receptor de glucocorticoide. |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11213526B2 (enExample) |
| EP (1) | EP3641780B1 (enExample) |
| JP (3) | JP7670462B2 (enExample) |
| AU (1) | AU2018289307B2 (enExample) |
| CA (1) | CA3065555A1 (enExample) |
| ES (1) | ES3043682T3 (enExample) |
| MX (1) | MX393313B (enExample) |
| WO (1) | WO2018236749A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3641780B1 (en) | 2017-06-20 | 2025-09-10 | Corcept Therapeutics Incorporated | Treatment of neuroepithelial tumors using selective glucocorticoid receptor modulators |
| JP7196201B2 (ja) | 2018-06-04 | 2022-12-26 | コーセプト セラピューティクス， インコーポレイテッド | ピリミジンシクロヘキセニル糖質コルチコイドレセプター調節因子 |
| JP7516394B2 (ja) | 2019-01-22 | 2024-07-16 | アクリベス ビオメディカル ゲーエムベーハー | 皮膚創傷治癒不全を治療するための選択的グルココルチコイド受容体モジュレーター |
| AU2021266739B2 (en) | 2020-05-06 | 2024-11-28 | Corcept Therapeutics Incorporated | Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators |
| CA3182272A1 (en) | 2020-05-06 | 2021-11-11 | Corcept Therapeutics Incorporated | Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators |
| KR20230124020A (ko) | 2020-12-21 | 2023-08-24 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 피리미딘 시클로헥실 글루코코르티코이드 수용체 조절제의제조 방법 |
| WO2024050500A1 (en) * | 2022-09-02 | 2024-03-07 | Corcept Therapeutics Incorporated | Methods of assessing selective glucocorticoid receptor modulation and of identifying and treating patients likely to benefit from glucocorticoid receptor modulation |
| WO2025255357A1 (en) * | 2024-06-06 | 2025-12-11 | Corcept Therapeutics Incorporated | Methods for preparing and maintaining livers and portions thereof for liver transplantation |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| US4296206A (en) | 1980-04-30 | 1981-10-20 | United States Of America | Irreversible anti-glucocorticoids |
| US4978657A (en) | 1981-01-09 | 1990-12-18 | Roussel Uclaf | Novel 11β-substituted-19-nor-steroids |
| ZA8231B (en) | 1981-01-09 | 1982-11-24 | Roussel Uclaf | New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained |
| FR2528434B1 (fr) | 1982-06-11 | 1985-07-19 | Roussel Uclaf | Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament |
| FR2522328B1 (fr) | 1982-03-01 | 1986-02-14 | Roussel Uclaf | Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments |
| FR2639045B2 (fr) | 1982-03-01 | 1994-07-29 | Roussel Uclaf | Nouveaux produits derives de la structure 3-ceto-delta-4,9-19-nor steroides et leur application comme medicaments |
| DE3438994A1 (de) | 1984-10-22 | 1986-04-24 | Schering AG, Berlin und Bergkamen, 1000 Berlin | Antigestagene, glukokortikoide und prostaglandine zur geburtseinleitung oder fuer den schwangerschaftsabbruch |
| FR2576025B1 (fr) | 1985-01-14 | 1987-01-23 | Roussel Uclaf | Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant |
| AU580843B2 (en) | 1985-02-07 | 1989-02-02 | Schering Aktiengesellschaft | 11``-phenyl-gonanes, their manufacture and pharmaceutical preparations containing them |
| DE3506785A1 (de) | 1985-02-22 | 1986-08-28 | Schering AG, Berlin und Bergkamen, 1000 Berlin | 11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate |
| US5380840A (en) | 1985-09-12 | 1995-01-10 | The Upjohn Company | Triazinylpiperazinyl steroids |
| FR2598421B1 (fr) | 1986-05-06 | 1988-08-19 | Roussel Uclaf | Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant |
| DE3761308D1 (de) | 1986-07-23 | 1990-02-08 | Akzo Nv | 18-phenylestrane-derivate. |
| DE3625315A1 (de) | 1986-07-25 | 1988-01-28 | Schering Ag | 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate |
| US4861763A (en) | 1986-09-17 | 1989-08-29 | Research Triangle Institute | 17 α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and their progestational use |
| US4774236A (en) | 1986-09-17 | 1988-09-27 | Research Triangle Institute | 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them |
| US5071773A (en) | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
| US4921638A (en) | 1986-11-05 | 1990-05-01 | The Upjohn Company | 17β-cyano-9α,17α-dihydroxyandrost-4-en-3-one |
| DE3708942A1 (de) | 1987-03-18 | 1988-09-29 | Schering Ag | 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate |
| DE3723788A1 (de) | 1987-07-16 | 1989-01-26 | Schering Ag | 11(beta)-phenyl-4,9,15-estratriene, deren herstellung und diese enthaltende pharmazeutische praeparate |
| FR2618783B1 (fr) | 1987-07-30 | 1991-02-01 | Roussel Uclaf | Nouveaux 17-aryle steroides, leurs procedes et des intermediaires de preparation comme medicaments et les compositions pharmaceutiques les renfermant |
| JP2785023B2 (ja) | 1987-12-30 | 1998-08-13 | ルセル―ユクラフ | １７α位置を置換された１７β―ＯＨ―１９―ノルステロイドの新誘導体、その製造方法、その薬剤としての使用及びそれを含有する製薬組成物 |
| DE3820948A1 (de) | 1988-06-16 | 1989-12-21 | Schering Ag | 10ss, 11ss-ueberbrueckte steroide |
| US4954490A (en) | 1988-06-23 | 1990-09-04 | Research Triangle Institute | 11 β-substituted progesterone analogs |
| US5348729A (en) | 1988-11-30 | 1994-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | Evaluative means for detecting inflammatory reactivity |
| DD289541A5 (de) | 1989-08-04 | 1991-05-02 | ��@�K@�������������@�K@��������������@��������k�� | Verfahren zur herstellung von 11beta-aryl-16 alpha, 17 alph-cyclohexanoestra-4,9-dienen |
| US5276023A (en) | 1989-08-08 | 1994-01-04 | Roussel Uclaf | 19-nor-steroid esters |
| FR2651233B1 (fr) | 1989-08-23 | 1991-12-13 | Roussel Uclaf | Nouveaux acides omega-phenylamino alcanouiques substitues sur le noyau aromatique par un radical derive de 19-norsterouides, leur procede de preparation, leur application a titre de medicaments et les compositions les renfermant. |
| US5173405A (en) | 1990-01-23 | 1992-12-22 | The United States Of America As Represented By The Department Of Health And Human Services | Use of arsenite to reversibly block steroid binding to glucocorticoid receptors in the presence of other steroid receptors |
| US5616458A (en) | 1990-03-14 | 1997-04-01 | Board Of Regents, University Of Tx System | Tripterygium wilfordii hook F extracts and components, and uses thereof |
| DE4042004A1 (de) | 1990-12-22 | 1992-06-25 | Schering Ag | 14(beta)-h-, 14- u. 15-en-11(beta)-aryl-4-estrene |
| US5215916A (en) | 1991-06-19 | 1993-06-01 | The United States Of America As Represented By The Department Of Health & Human Services | Super glucocorticoid receptors: receptors with increased affinity and specificity for glucocorticoid steriods |
| US5439913A (en) | 1992-05-12 | 1995-08-08 | Schering Aktiengesellschaft | Contraception method using competitive progesterone antagonists and novel compounds useful therein |
| ZA953976B (en) | 1994-05-19 | 1996-01-19 | Akzo Nobel Nv | 11,21-bisphenyl-19-norpregnane derivatives |
| US6051573A (en) | 1994-06-28 | 2000-04-18 | Alcon Laboratories, Inc. | Treatment of GLC1A glaucoma with non-steroidal glucocorticoid antagonists |
| DE69531998T2 (de) | 1994-12-22 | 2004-07-22 | Ligand Pharmaceuticals, Inc., San Diego | Steroidrezeptor-modulator verbindungen und methoden |
| US5688808A (en) | 1994-12-22 | 1997-11-18 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
| IL118974A (en) | 1995-08-17 | 2001-09-13 | Akzo Nobel Nv | History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them |
| US5929058A (en) | 1996-12-24 | 1999-07-27 | Zymogenetics, Inc. | Treatment agents and methods for treating type II diabetes and symptoms of type II diabetes |
| EP0903146A1 (en) | 1997-09-23 | 1999-03-24 | Applied Research Systems ARS Holdings N.V. | 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid |
| DE10038639A1 (de) | 2000-07-28 | 2002-02-21 | Schering Ag | Nichtsteroidale Entzündungshemmer |
| IL180679A0 (en) | 2000-10-27 | 2009-02-11 | Pfizer Prod Inc | Process for the preparation of non-steroidal glucocorticoid receptor modulators |
| AU2002366217A1 (en) | 2001-11-23 | 2003-06-10 | Akzo Nobel N.V. | Treatment of major depressive disorder using glucocorticoid receptor antagonists |
| PT1735308E (pt) | 2004-03-09 | 2008-12-02 | Corcept Therapeutics Inc | Moduladores dos receptores de glucocorticóides de azadecalina de anel fundido |
| US20060205700A1 (en) * | 2005-03-09 | 2006-09-14 | May Flavia S | Non invasive method for prevention and treatment of cancer |
| EP2429529B1 (en) | 2009-05-12 | 2015-01-14 | Corcept Therapeutics, Inc. | Solid forms and process for preparing |
| EP2440577A4 (en) | 2009-06-12 | 2013-01-23 | Acceleron Pharma Inc | SHORTEN ACTRIIB FC FUSION PROTEINS |
| US8710035B2 (en) | 2010-03-24 | 2014-04-29 | The University Of Chicago | Methods and compositions related to glucocorticoid receptor antagonists and breast cancer |
| JP6039587B2 (ja) * | 2011-03-18 | 2016-12-07 | コーセプト セラピューティクス， インコーポレイテッド | ピリミジンシクロヘキシルグルココルチコイドレセプター調節因子 |
| PT3111950T (pt) * | 2012-02-24 | 2021-10-19 | Univ Chicago | Métodos e composições relacionadas com antagonismo recetor de glucocorticoide e cancro da próstata |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| PL3590517T3 (pl) | 2012-05-25 | 2021-09-20 | Corcept Therapeutics Incorporated | Modulatory receptorów glukokortykoidowych typu azadekaliny skondensowanej z heteroaryloketonem |
| US8986677B2 (en) | 2012-07-30 | 2015-03-24 | Pop Test Cortisol Llc | Therapeutic compositions and methods |
| BR112016011826B1 (pt) | 2013-11-25 | 2022-09-27 | Corcept Therapeutics, Inc | Composto, composição farmacêutica e uso do referido composto |
| EP3265127B1 (en) | 2015-03-02 | 2024-02-21 | Corcept Therapeutics, Inc. | Mifepristone and octreotide for use in the treatment of cushing's syndrome in a patient having an adrenocorticotropic hormone (acth)-secreting pancreatic neuroendocrine tumor |
| IL297201A (en) * | 2016-03-01 | 2022-12-01 | Corcept Therapeutics Inc | Use of glucocorticoid receptor modulators to increase the activity of checkpoint inhibitors |
| WO2018209142A2 (en) * | 2017-05-10 | 2018-11-15 | Corcept Therapeutics, Inc. | Octahydro azadecalin formulations |
| EP3641780B1 (en) * | 2017-06-20 | 2025-09-10 | Corcept Therapeutics Incorporated | Treatment of neuroepithelial tumors using selective glucocorticoid receptor modulators |
-
2018
- 2018-06-18 EP EP18821665.9A patent/EP3641780B1/en active Active
- 2018-06-18 ES ES18821665T patent/ES3043682T3/es active Active
- 2018-06-18 CA CA3065555A patent/CA3065555A1/en active Pending
- 2018-06-18 AU AU2018289307A patent/AU2018289307B2/en active Active
- 2018-06-18 JP JP2019570000A patent/JP7670462B2/ja active Active
- 2018-06-18 MX MX2019015385A patent/MX393313B/es unknown
- 2018-06-18 WO PCT/US2018/038075 patent/WO2018236749A2/en not_active Ceased
- 2018-06-18 US US16/620,832 patent/US11213526B2/en active Active
-
2021
- 2021-11-19 US US17/531,682 patent/US11793810B2/en active Active
-
2022
- 2022-08-30 JP JP2022136739A patent/JP2022164775A/ja active Pending
-
2023
- 2023-09-15 US US18/369,071 patent/US12263169B2/en active Active
-
2025
- 2025-02-20 JP JP2025026258A patent/JP2025071259A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11213526B2 (en) | 2022-01-04 |
| EP3641780A4 (en) | 2021-02-24 |
| JP2022164775A (ja) | 2022-10-27 |
| JP7670462B2 (ja) | 2025-04-30 |
| EP3641780A2 (en) | 2020-04-29 |
| EP3641780B1 (en) | 2025-09-10 |
| CA3065555A1 (en) | 2018-12-27 |
| US20200147082A1 (en) | 2020-05-14 |
| US11793810B2 (en) | 2023-10-24 |
| WO2018236749A3 (en) | 2019-01-24 |
| JP2025071259A (ja) | 2025-05-02 |
| US20220079946A1 (en) | 2022-03-17 |
| ES3043682T3 (en) | 2025-11-25 |
| AU2018289307B2 (en) | 2024-02-01 |
| US12263169B2 (en) | 2025-04-01 |
| AU2018289307A1 (en) | 2019-12-19 |
| US20240009194A1 (en) | 2024-01-11 |
| WO2018236749A2 (en) | 2018-12-27 |
| JP2020524152A (ja) | 2020-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX393313B (es) | Metodos de tratamiento de tumores neuroepiteliales usando moduladores selectivos del receptor de glucocorticoide. | |
| EA201991772A1 (ru) | Способ лечения рака предстательной железы с использованием комбинации на основе модулятора андрогенного рецептора | |
| MX2021005398A (es) | Terapia del cancer con celulas inmunitarias anti-cd33. | |
| MX2021004821A (es) | Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia. | |
| MX2020008244A (es) | Composiciones y metodos para el tratamiento del cancer y de trastornos inmunitarios usando bacterias de veillonella. | |
| CL2019002871A1 (es) | Terapia combinada para cáncer de próstata. | |
| MX2019002703A (es) | Moduladores del receptor de glucosocorticoides para tratar el cancer pancreatico. | |
| CO2018013747A2 (es) | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos | |
| SG10201902664RA (en) | Combination therapy for treating cancer | |
| CL2017001180A1 (es) | Dianhidrogalactitol en conjunto con radiación para tratar carcinoma de células no pequeñas del pulmón y glioblastoma multiforme | |
| MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
| EA201790332A1 (ru) | Дополнительная терапия 25-гидроксивитамином d | |
| CL2009001011A1 (es) | Uso del compuesto 21-metoxi-17a-acetoxi-11ß-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona (cdb-4124) para tratar el cancer de mama; y uso de la combinacion de cdb-4124 con un inhibidor de aromatasa. | |
| NZ727709A (en) | Pharmaceutical composition comprising 5alpha-reductase inhibitor | |
| EA201890812A1 (ru) | Дополнительная терапия 25-гидроксивитамином d и изделия для этого | |
| BR112015026257A2 (pt) | terapia de combinação compreendendo um composto di-hidropirazino-pirazina e um antagonista do receptor de andrógeno para tratar câncer de próstata | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| MX2019013862A (es) | Terapia de combinacion. | |
| EA201001853A1 (ru) | Фармацевтическая комбинация | |
| PH12022551493A1 (en) | Synthetic triterpenoids with nitrogen-based substituents at c-17 and methods of use thereof | |
| MY197942A (en) | Adjuvant therapy for use in prostate cancer treatment | |
| MX2020003830A (es) | Métodos para tratar el cáncer de próstata mediante la administración de acetato de abiraterona más prednisona con terapia de privación de andrógenos. | |
| ZA202201070B (en) | Focal treatment of prostate cancer | |
| AR105142A1 (es) | Métodos de tratamiento del glioblastoma multiforme con terapia de células t | |
| MX2020010219A (es) | Antagonistas de gaba-a para tratar trastornos por abstinencia de sustancia. |